RNA Analytical/Quality Videos

  1. Rethinking pDNA Analytical Methods 10/29/2026

    Are pDNA analytical methods telling the full truth—or leading us astray? Here, Advancing RNA’s panel of industry experts confront the discrepancies between standard assays, challenge the biopharma industry’s dangerous "addiction" to agarose gels, and weigh the regulatory hurdles of adopting Next-Generation Sequencing (NGS) for characterization versus batch release. 

  2. Decoding Regulatory Expectations: The Art Of A Successful IND Submission 6/24/2025

    Companies often underestimate the information required for IND submissions, particularly in a sector that’s as diverse as the mRNA sector. Here, former FDA reviewer Tiffany Lucas shares some of the missteps companies can make when first approaching the FDA with their IND. CureVac’s Ulrike Jägle furthers the discussion, offering a critical best practice she and her colleagues rely upon as well to streamline their regulatory interactions.

  3. Assessing The Quality & Maturity Of The Next-Gen Oligo Supply Chain 12/3/2025

    As our molecules grow more complicated, so, too, does the supply chain. Here, Advancing RNA Live speakers Khaled Yamout & Camp4’s Satya Kuchimanchi talk through how this growth challenges our understanding of raw material quality and how sponsors can better assess their suppliers.

  4. Robust And Cost-Effective mRNA Capping 12/8/2025

    Master the essential strategies for cost-effective and robust mRNA capping at industrial scale. Learn how to successfully evaluate new materials and optimize your synthesis process for maximum efficiency and yield.

  5. Real-Time Monitoring Of Higher-Order Structure Of RNAs 9/10/2025

    Learn how a new biophysical characterization strategy can enhance RNA therapeutic candidate screening and formulation development through a deeper understanding of RNA structure under native conditions.

  6. Breaking New Ground: MHRA Embraces A Future With Patient-Specific mRNA 6/24/2025

    In this Advancing RNA clip, panelists Ulrike Jägle and Tiffany Lucas unpack the benefits they see to the MHRA's new guidance on mRNA cancer immunotherapies, including the agency’s support for bioinformatics approaches and its burgeoning framework for developing and justifying a truly personalized medicine.

  7. Are We Missing mRNA Drug Substance CQAs? 6/9/2026

    As a field, we’ve been aligned around CQAs for our mRNA drug substances. However, differences in translation between highly similar mRNAs (i.e., (same sequence, same design, different manufacturers) raises the question of whether we’re missing any QAs/CQAs. Here, Advancing RNA Live panelists Elaine Peters and Ilya Shestolapov share their take. 

  8. Primates, Patents, And Progress: Advancements In Rational LNP Design 2/24/2026

    In this opening Advancing RNA Live clip, NanoVation Therapeutics’ Dominik Witzigmann and Stealth Co’s John Zuris share the scientific advancements they’ve been watching most keenly in the LNP space, as well as some of the evolutions they’re seeing in the overall quality of our RNA-LNP products.

  9. Improve Bioanalysis Workflows With Integrated Technologies 8/18/2026

    Improve bioanalysis workflows with integrated technologies designed for sensitive biomolecules. Explore how biocompatible systems can support sample integrity, reliable performance, and evolving needs.

  10. The Evolving CMC Landscape For mRNA-LNPs 2/24/2026

    In this Advancing RNA Live clip, CMC consultant Sujit Jain unpacks the levels of maturity he’s observed in process and analytical development, as well as supply chain. While vaccines and liver-targeting therapeutics boast what we can call a reproducible platform today, targeted LNP therapies introduce a handful of scale-up sensitivities and characterization hurdles.